ClinicalTrials.Veeva

Menu

Bariatric Arterial Embolization for Morbid Obesity (BAEMO)

S

Southeast University

Status and phase

Unknown
Phase 3

Conditions

Morbid Obesity

Treatments

Behavioral: healthy diet and exercise
Procedure: left gastric artery embolization

Study type

Interventional

Funder types

Other

Identifiers

NCT02786108
2015ZDSYLL068.0

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and effectiveness of left gastric artery embolization(bariatric arterial embolization) for morbid obesity. When the target vessel is blocked, some of the body's signals for feeling hungry will be suppressed and lead to weight loss.

Although there are many ways to treat morbid obesity, surgery is currently the only effective method to be confirmed. But surgical treatment is likely to carry a high risk of treatment-related complications, such as fistula or intestinal obstruction, etc. This study is designed to help treat obesity using a method of transvascular interventional therapy, which is minimally invasive and non-surgical.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Body mass index (BMI) >30.

  2. No history of gastrointestinal surgery.

  3. Willing, able and mentally competent to provide written informed consent.

  4. Suitable for protocol therapy as determined by the interventional radiology Investigator.

  5. Adequate hematological, hepatic and renal function as follows:

    Hematological Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L INR <1.5 Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/L Renal Estimated GFR > 60ml/min.1.73m2

  6. Aged between18 and 65 years old.

  7. More than one year's follow-up can be obtained reliably

Exclusion criteria

  1. Prior history of gastric pancreatic, hepatic, and/or splenic surgery
  2. Prior embolization to the stomach, spleen or liver
  3. Prior or current history of peptic ulcer disease
  4. Significant risk factors for peptic ulcer disease including daily NSAID use and smoking.
  5. Portal venous hypertension or cirrhosis
  6. Less than 18 years or older than 65 years of age
  7. Known aortic pathology such as aneurysm or dissection renal insufficiency as evidenced by an estimated glomerular filtration rate of < 60 milliliters per minute an estimated glomerular filtration rate of < 60 milliliters per minute
  8. Major comorbidity such as cancer, significant cardiovascular disease, or peripheral arterial disease
  9. Pregnant or intend to become pregnant within one year Known history of allergy to iodinated contrast media
  10. Patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, and uncontrolled depression, and mental/cognitive impairment that limits the individual's ability to understand the proposed therapy.
  11. Patients currently taking or requiring chronic use of NSAID or steroid medications

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

50 participants in 2 patient groups

left gastric artery embolization
Experimental group
Description:
Patients undergoing left gastric artery embolization
Treatment:
Procedure: left gastric artery embolization
healthy diet and exercise
Active Comparator group
Description:
Patients undergoing healthy diet and exercise
Treatment:
Behavioral: healthy diet and exercise

Trial contacts and locations

1

Loading...

Central trial contact

Zhibin Bai

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems